Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dragonfly Therapeutics
Biotech
AbbVie halts development of Dragonfly cancer asset in midflight
AbbVie has terminated a phase 1 trial of the natural killer-cell engager ABBV-303, licensed from Dragonfly as part of an ongoing partnership.
Darren Incorvaia
Oct 29, 2025 1:47pm
RFK Jr. will divest interests in biotechs if HHS role confirmed
Jan 22, 2025 1:37pm
Dragonfly asset flies home as BMS deal crumbles
Feb 6, 2023 11:20am
New federal biotech commission taps 12 members—Chutes & Ladders
Feb 3, 2023 10:20am
Novel cancer vaccines look beyond T cells to better fight tumors
May 27, 2022 2:00pm
Gilead joins Big Pharma peers at Dragonfly's pond in $300M deal
May 2, 2022 9:50am
